BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 30578883)

  • 1. Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
    Steinfeld J; Bradford ES; Brown J; Mallett S; Yancey SW; Akuthota P; Cid MC; Gleich GJ; Jayne D; Khoury P; Langford CA; Merkel PA; Moosig F; Specks U; Weller PF; Wechsler ME
    J Allergy Clin Immunol; 2019 Jun; 143(6):2170-2177. PubMed ID: 30578883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Akuthota P; Jayne D; Khoury P; Klion A; Langford CA; Merkel PA; Moosig F; Specks U; Cid MC; Luqmani R; Brown J; Mallett S; Philipson R; Yancey SW; Steinfeld J; Weller PF; Gleich GJ;
    N Engl J Med; 2017 May; 376(20):1921-1932. PubMed ID: 28514601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis.
    Wechsler ME; Nair P; Terrier B; Walz B; Bourdin A; Jayne DRW; Jackson DJ; Roufosse F; Börjesson Sjö L; Fan Y; Jison M; McCrae C; Necander S; Shavit A; Walton C; Merkel PA;
    N Engl J Med; 2024 Mar; 390(10):911-921. PubMed ID: 38393328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Tsurikisawa N; Oshikata C; Watanabe M; Fukuda N; Yamaguchi T; Kiyohara H; Kaneko T
    Int Arch Allergy Immunol; 2021; 182(8):744-756. PubMed ID: 33887721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of conventional immunosuppressants in relapsing or refractory eosinophilic granulomatosis with polyangiitis: evidence from a Canadian single-centre cohort.
    Doubelt I; Pulenzas N; Carette S; Pagnoux C;
    Clin Exp Rheumatol; 2020; 38 Suppl 124(2):171-175. PubMed ID: 32167871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis.
    Ennis D; Lee JK; Pagnoux C
    Expert Opin Biol Ther; 2019 Jul; 19(7):617-630. PubMed ID: 31146595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolated CNS involvement in eosinophilic granulomatosis with polyangiitis treated with mepolizumab: A case report.
    Son H; Lee WJ; Moon J; Yoon S; Jung KH; Park KI; Lee SK; Chu K
    J Neuroimmunol; 2021 Jun; 355():577551. PubMed ID: 33773378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan.
    Yamane T; Hashiramoto A
    Arthritis Res Ther; 2023 Jun; 25(1):110. PubMed ID: 37365612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mepolizumab as a glucocorticoid-sparing agent in eosinophilic granulomatosis with polyangiitis (EGPA): is a lower dose sufficient?
    Vergles M; Matković Z; Lalić K; Trkanjec JT; Tudorić N
    J Asthma; 2021 Dec; 58(12):1675-1679. PubMed ID: 32962455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype.
    Terrier B; Jayne DRW; Hellmich B; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Akuthota P; Khoury P; Baylis L; Wechsler ME;
    ACR Open Rheumatol; 2023 Jul; 5(7):354-363. PubMed ID: 37312233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational Study.
    Bettiol A; Urban ML; Dagna L; Cottin V; Franceschini F; Del Giacco S; Schiavon F; Neumann T; Lopalco G; Novikov P; Baldini C; Lombardi C; Berti A; Alberici F; Folci M; Negrini S; Sinico RA; Quartuccio L; Lunardi C; Parronchi P; Moosig F; Espígol-Frigolé G; Schroeder J; Kernder AL; Monti S; Silvagni E; Crimi C; Cinetto F; Fraticelli P; Roccatello D; Vacca A; Mohammad AJ; Hellmich B; Samson M; Bargagli E; Cohen Tervaert JW; Ribi C; Fiori D; Bello F; Fagni F; Moroni L; Ramirez GA; Nasser M; Marvisi C; Toniati P; Firinu D; Padoan R; Egan A; Seeliger B; Iannone F; Salvarani C; Jayne D; Prisco D; Vaglio A; Emmi G;
    Arthritis Rheumatol; 2022 Feb; 74(2):295-306. PubMed ID: 34347947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study.
    Nolasco S; Portacci A; Campisi R; Buonamico E; Pelaia C; Benfante A; Triggiani M; Spadaro G; Caiaffa MF; Scioscia G; Detoraki A; Valenti G; Papia F; Tomasello A; Crimi N; Scichilone N; Pelaia G; Carpagnano GE; Crimi C
    Front Immunol; 2023; 14():1204444. PubMed ID: 37457743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
    Condreay LD; Parham LR; Qu XA; Steinfeld J; Wechsler ME; Raby BA; Yancey SW; Ghosh S
    Rheumatol Int; 2020 Aug; 40(8):1301-1307. PubMed ID: 32009195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis.
    Pradhan RR; Nepal G; Mandal S
    Pulm Med; 2019; 2019():4376380. PubMed ID: 30941214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab has clinical benefits including oral corticosteroid sparing irrespective of baseline EGPA characteristics.
    Jayne DRW; Terrier B; Hellmich B; Khoury P; Baylis L; Bentley JH; Steinfeld J; Yancey SW; Kwon N; Wechsler ME; Akuthota P
    ERJ Open Res; 2024 Jan; 10(1):. PubMed ID: 38196889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series.
    Detoraki A; Tremante E; Poto R; Morelli E; Quaremba G; Granata F; Romano A; Mormile I; Rossi FW; de Paulis A; Spadaro G
    Respir Res; 2021 Jun; 22(1):185. PubMed ID: 34162391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Pediatric Case of Relapsing Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab.
    Nara M; Saito M; Abe F; Komatsuda A; Wakui H; Takahashi N
    Intern Med; 2019 Dec; 58(24):3583-3587. PubMed ID: 31391393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis.
    Ríos-Garcés R; Prieto-González S; Hernández-Rodríguez J; Arismendi E; Alobid I; Penatti AE; Cid MC; Espígol-Frigolé G
    Eur J Intern Med; 2022 Jan; 95():61-66. PubMed ID: 34535374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of eosinophilic granulomatosis with polyangiitis during the clinical course of microscopic polyangiitis: A case report.
    Ide H; Shimizu T; Koike Y; Abe K; Shigematsu K; Nishihata S; Kojima K; Ichinose K; Kawakami A
    Medicine (Baltimore); 2022 Nov; 101(44):e31401. PubMed ID: 36343053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two cases of refractory eosinophilic granulomatosis with polyangiitis wherein mepolizumab was effective against pulmonary and ear lesions.
    Ushio Y; Wakiya R; Kato M; Kameda T; Nakashima S; Shimada H; Mansour MMF; Sugihara K; Miyashita T; Kadowaki N; Dobashi H
    Mod Rheumatol Case Rep; 2021 Jul; 5(2):327-332. PubMed ID: 33533698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.